全球铁粒幼细胞贫血市场 – 行业趋势和 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球铁粒幼细胞贫血市场 – 行业趋势和 2030 年预测

  • Pharmaceutical
  • Upcoming Report
  • Oct 2023
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Sideroblastic Anemia Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 4.17 Billion
Diagram Market Size (Forecast Year)
USD 7.07 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Eisai
  • Pfizer
  • Sanofi
  • Teva Pharmaceuticals Industries
  • Novartis

>全球铁粒幼细胞贫血市场,按药物类别(口服吡哆醇、铁螯合剂、去铁胺或口服螯合剂等)、治疗(药物、输血、静脉切开术等)、症状(疲劳、虚弱、心悸、气短、头痛、易怒、胸痛等)、给药方式(注射、口服等)、分销渠道(医院药房、零售药房、网上药房)、最终用户(医院、家庭护理、专科诊所等)划分 - 行业趋势和预测到 2030 年。

铁粒幼细胞贫血市场

铁粒幼细胞贫血市场分析和规模

铁粒幼细胞性贫血是指由于红细胞生成过程中铁的异常利用而引起的一种贫血。各种形式的铁粒幼细胞性贫血通常被描述为骨髓中存在环状铁粒幼细胞。环状铁粒幼细胞被定义为红细胞前体,其线粒体中存在非血红素铁沉积,这些铁沉积物在细胞核周围形成环状分布。铁形成的环覆盖细胞核边缘的至少三分之一。

全球范围内患有铁粒幼细胞贫血的人数增加是推动全球铁粒幼细胞贫血市场增长的主要因素之一。对于被诊断为 X 连锁铁粒幼细胞贫血的患者,对吡哆醇等药物的需求增加,以及治疗该疾病引起的各种并发症的技术的发展加速了市场的增长。制造商之间为开发新药而采取的收购策略和公司合作数量激增,以及人们对贫血相关疾病的认识不断提高,进一步影响了市场。此外,人口增长、医疗保健基础设施和技术的发展以及对研究活动的投资增加都对全球铁粒幼细胞贫血市场产生了积极影响。

Data Bridge Market Research 分析,全球铁粒幼细胞贫血市场在 2022 年为 41.7 亿美元,到 2030 年将飙升至 70.7 亿美元,预计在 2023-2030 年预测期内的复合年增长率为 6.9%。这表明市场价值。由于老龄化人口的增加,“医院”在全球铁粒幼细胞贫血市场的最终用户细分市场中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

铁粒幼细胞贫血市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021 (可定制为 2015-2020)

定量单位

收入(单位:十亿美元)、销量(单位:台)、定价(美元)

涵盖的领域

药物类别(口服吡哆醇、铁螯合剂、去铁胺或口服螯合剂、其他)、治疗(药物、输血、静脉切开术、其他)、症状(疲劳、虚弱、心悸、气短、头痛、易怒、胸痛、其他)、给药方式(注射、口服、其他)、分销渠道(医院药房、零售药房、网上药房)、最终用户(医院、家庭护理、专科诊所、其他)。

覆盖国家

美国、加拿大、墨西哥、秘鲁、巴西、阿根廷、南美洲其他地区、德国、意大利、英国、法国、西班牙、荷兰、比利时、瑞士、土耳其、俄罗斯、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、欧洲其他地区、日本、中国、印度、韩国、澳大利亚、新加坡、马来西亚、泰国、印度尼西亚、菲律宾、越南、亚太地区其他地区、南非、沙特阿拉伯、阿联酋、科威特、以色列、埃及、中东和非洲其他地区

涵盖的市场参与者

卫材株式会社(日本)、辉瑞公司(美国)、赛诺菲(法国)、梯瓦制药工业有限公司(以色列)、诺华公司(瑞士)、艾尔建(爱尔兰)、Merz Pharma(德国)、强生服务公司(美国)、罗氏公司(瑞士)、百时美施贵宝公司(美国)、艾伯维公司(美国)、礼来公司(美国)、武田制药有限公司(日本)、拜耳公司(德国)、百健(美国)、阿斯利康(英国)、VTV Therapeutics(美国)、H. Lundbeck A/S(丹麦)、TauRx Pharmaceuticals Ltd(英国)和第一三共株式会社(日本)

市场机会

  • 患者支持和生活质量
  • 罕见疾病研究资金

市场定义

铁粒幼细胞性贫血是指由于红细胞生成过程中铁的异常利用而引起的一种贫血。各种形式的铁粒幼细胞性贫血通常被描述为骨髓中存在环状铁粒幼细胞。环状铁粒幼细胞被定义为红细胞前体,其线粒体中存在非血红素铁沉积,这些铁沉积物在细胞核周围形成环状分布。铁形成的环覆盖细胞核边缘的至少三分之一。

全球铁粒幼细胞贫血市场动态

驱动程序

  • 基因研究与精准医疗

研究人员在了解与铁粒幼细胞贫血相关的基因突变和途径方面取得了重大进展。这些知识为开发靶向疗法和个性化治疗方案打开了大门,推动了该领域的研究和投资。

  • 诊断技术的进步

诊断工具方面的许多技术进步,例如基因检测和分子分析,使得识别和分类不同类型的铁粒幼细胞贫血变得更加容易。这使得诊断更加准确,治疗策略也更加有针对性。

机会

  • 罕见病研究和孤儿药认定

Sideroblastic anemia is considered a rare disease. Companies that focus on orphan drug development might find opportunities in this market, as governments and regulatory bodies often provide incentives and exclusivity for drugs targeting rare diseases.

Restraint/Challenge

  • Lack of Standardized Treatment

There is no standard treatment protocol for sideroblastic anemia, which can lead to variations in care and uncertainty in treatment outcomes.

This global sideroblastic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global sideroblastic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Sideroblastic Anemia Market Scope

Global sideroblastic anemia market is categorized into six notable segments which are based on the basis of drug class, treatment, symptoms, mode of administration, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Oral Pyridoxin
  • Iron Chelation
  • Deferoxamine
  • Oral Chelators
  • Others

Treatment

  • Drugs
  • Blood Transfusion
  • Phlebotomy
  • Others

Symptoms

  • Fatigue
  • Weakness
  • Palpitations
  • Shortness of Breath
  • Headaches
  • Irritability
  • Chest Pain
  • Others

Mode of Administration

  • Injectable
  • Oral
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End User

  • Homecare
  • Speciality
  • Hospitals
  • Clinics
  • Others

Global Sideroblastic Anemia Market Regional Analysis/Insights

The global sideroblastic anemia market is analyzed and market size information is provided by country, drug class, treatment, symptoms, mode of administration, distribution channel and end user as referenced above.

The countries covered in the global sideroblastic anemia market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

由于药物审批增加和该地区医疗基础设施完善,北美在全球铁粒幼细胞贫血市场占据主导地位。由于该地区医疗基础设施不断发展,预计亚太地区将在 2021 年至 2028 年的预测期内实现高增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

医疗保健基础设施增长安装基础和新技术渗透

全球铁粒幼细胞贫血市场还为您提供每个国家/地区资本设备医疗支出增长、全球铁粒幼细胞贫血市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对全球铁粒幼细胞贫血市场的影响的详细市场分析。数据涵盖 2015-2020 年的历史时期。  

竞争格局和全球铁粒幼细胞贫血市场份额分析

全球铁粒幼细胞贫血市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对全球铁粒幼细胞贫血市场的关注有关。

全球铁粒幼细胞贫血市场的一些主要参与者包括:

  • 卫材株式会社 (日本)
  • 辉瑞公司(美国)
  • 赛诺菲(法国)
  • Teva Pharmaceuticals Industries Ltd.(以色列)
  • 诺华公司(瑞士)
  • 艾尔建(爱尔兰)
  • Merz Pharma(德国)
  •  强生服务公司(美国)
  • F. Hoffmann-La Roche Ltd(瑞士)
  • 百时美施贵宝公司 (美国)
  • AbbVie Inc.(美国)
  • 礼来 Eli Lilly and Company(美国)
  • 武田药品工业株式会社 (日本)
  • 拜耳公司(德国)
  •  Biogen(美国)
  • 阿斯利康(英国)
  • VTV Therapeutics(美国)
  • H. Lundbeck A/S(丹麦)
  • TauRx Pharmaceuticals Ltd(英国)
  • 第一三共株式会社(日本)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Drug Class (Oral Pyridoxine, Iron Chelation, Deferoxamine or Oral Chelators, Others), Treatment (Drugs, Blood Transfusion, Phlebotomy, Others), Symptoms (Fatigue, Weakness, Palpitations, Shortness Of Breath, Headaches, Irritability, Chest Pain, Others), Mode of Administration (Injectable, Oral, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030. .
The Global Sideroblastic Anemia Market size was valued at USD 4.17 USD Billion in 2022.
The Global Sideroblastic Anemia Market is projected to grow at a CAGR of 6.9% during the forecast period of 2023 to 2030.
The major players operating in the market include Eisai, Pfizer, Sanofi, Teva Pharmaceuticals Industries, Novartis, Allergan, Merz Pharma, Johnson & Johnson Services, F. Hoffmann La Roche, Bristol Myers Squibb Company, AbbVie, Lilly, Takeda Pharmaceutical Company, Bayer, Biogen, AstraZeneca, VTV Therapeutics, H. Lundbeck, TauRx Pharmaceuticals, DAIICHI SANKYO COMPANY.
The market report covers data from the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.